Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01903122 · ClinicalTrials.gov registry record · Early Phase 1
Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions
A Early Phase 1 study, sponsored by Roxane Laboratories.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 26
- Enrollment target
NCT01903122: Completed Early Phase 1 study, sponsored by Roxane Laboratories.
NCT01903122 is a Early Phase 1 study that has completed, run by Roxane Laboratories. The registered enrollment target is 26 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (51% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01903122, a Early Phase 1 study, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fasted conditions
Primary Outcome
The comparison of the pharmacokinetic parameters of the test and reference products
Interventions
- DRUG Cevimeline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2009-02 |
| Est. Completion | 2009-02 |
| Phase | Early Phase 1 |
What the finished NCT01903122 record still lists
NCT01903122 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (51% lower).
The record links to 0 conditions, and to 1 intervention - of which Cevimeline is the first listed.
NCT01903122 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01903122 about?
NCT01903122 is a clinical study titled "Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions". The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fasted conditions
What is the current status of trial NCT01903122?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 26 participants. The study started on 2009-02. Estimated completion is 2009-02.
What interventions are being tested in trial NCT01903122?
The interventions under investigation include: Cevimeline (DRUG).
Who is sponsoring clinical trial NCT01903122?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01903122's enrollment target sits among peer trials
26 977th of 2000 higher than 1,002 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia